The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Truth is there really aint many in under 5p let alone 10p!! Trading volume here has been very low pre today
Well my 8p investment last year looks like it may recoup finally
I think in six months time, 5p will look like a steal.
But DYOR and make your own mind up.
Thanks Doppo
Let him go Doppo he ain’t worth it mate
Cricket,
I would agree with BB7
In my opinion this is still a buy, it has lots to give yet!
If I had spare cash, I'd be buying.
Just my opinion
Thanks Former, it's a no then.
You really should buy based on some research not our comments, but if you want the opinion of a stranger I’d say it definitely is worth buying
DYOR, review the RNS, take a look at the financials, cash burn, cash runway etc.
No replies, guessing it's not worth buying at 5?
Missed out on this earlier in the week, big mistake. Expecting more of a rise?
JJ7,
Today is a very good day. Lots more news to come, my heart rate is returning to normal. It's been a long 4 years!
Might get a take-away tonight :)
Thanks to the top posters on here for all the support.
Enjoy the sun!
Unfortunately I've already added to the hilt!
Well done all lth and to those who kept their nerve.
Nice comment from Nukem yesterday
It was great to see Bastiaan Driehuys here and that the interest in Polarean‘s gamechaniging technology is reaching more and more people.
We are very thankful for this great partnership.
Thats the 4th firm full system purchase, 15 triallists very hot leads to convert. Convert they will.
Well on track for this year's targets.
4p looks good to me on the basis that they have a US Patent on the technology and a firm order into a major research hospital. Just a matter of patience imo before the share price climbs substantially from 4p.
Forgot about the HMRC money thats due very soon. That will send this up much higher
Buggers pulled the trade at 3.85 and went negotiated ... grrrr so looks like 4p top up
O The Company has obtained advanced assurance from His Majesty's Revenue & Customs (HMRC) to confirm £2.5m ($3.1m) of Enterprise Investment Scheme availability
This should be coming soon
Beautiful
Was scanning the RNS and saw this news. Impressed, placed a modest fill or kill with HL at 4p a share. Hoping to get in close to the bottom and ride a future wave of good news.
On top of the trialists. This is the sign of the surge upwards to never look back. Well done holders who didn't papp themselves.
Polarean Imaging plc
("Polarean" or the "Company")
New Xenon MRI System order received
Top-tier academic hospital becomes the first de novo site in the southeast U.S
Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of lung function, announces that it has received its second de novo order for a new Xenon MRI System from the University of Alabama at Birmingham ("UAB") Hospital, a top-tier academic hospital in the south-eastern region of the U.S. The 'de novo' designation indicates that UAB Hospital is acquiring this innovative imaging technology for the first time, without a prior research programme utilising the Polarean Xenon MRI System. This milestone underscores the increasing adoption and impact of Polarean's cutting-edge MRI solutions.
The Company expects to install the new system later this year and will collaborate closely with the hospital team, as it does with its existing clinical sites, to develop a strong Xenon MRI programme. This programme will support clinical imaging, NIH-funded research, and pharmaceutical-sponsored trials, aligning with Polarean's commitment to advancing medical research and patient care.
Christopher R. von Jako, Ph.D., CEO of Polarean, said: "Expanding our user base is one of the five key growth pillars we identified last year, and so I am delighted to have received our second de novo system order from UAB Hospital, a prestigious top-tier U.S. academic facility. Hospital acquisition of new capital equipment can be a lengthy process, and so momentum continues to build for our sales success. Contingent on the installation of this polariser system, and the two additional previously announced system orders, during 2024, the Company has completed sales and firm orders as of today that would result in 2024 revenue of approximately $2.5M. We expect additional orders to come in this year that will result in additional 2024 revenue. We are very excited to see that our commercial growth strategy is yielding tangible results."
Alex Dusek, Chief Commercial Officer of Polarean, said: "Feedback on the Polarean technology from physicians continues to be overwhelmingly positive, and we look forward to working closely with clinicians and scientists at UAB hospital to help establish the approved use of XENOVIEW™ for the visualisation of ventilation patients aged 12 and older. We are continuing to have productive meetings with our other high-priority centres, as they work through the necessary steps of the value assessment and procurement process. These centres are becoming increasingly aware of our technology's clinical, scientific, and economic value in lung ventilation, as well as research into gas exchange and cardiopulmonary for future applications, where we recently strengthe
Polarean Imaging PLC - New Xenon MRI System order received #POLX @PolareanImaging https://www.voxmarkets.co.uk/rns/announcement/a0953ce7-6ab7-47fc-90d5-c305adae38a8 #voxmarkets undefined
Outstanding.